Inspire Medical Systems (NYSE:INSP) Releases FY 2026 Earnings Guidance

Key Points

• FY2026 guidance of EPS $0.75–$1.25 and revenue $825–$875M was well below Wall Street consensus (EPS 1.99; revenue $961.2M).
• Shares fell ~3.4% to $54.77 on the update; the stock trades far below its 52‑week high ($163.35) with a market cap of about $1.58B and a P/E of 11.0.
• The company beat last quarter’s estimates (EPS $0.10 vs. -$0.28 expected; revenue $204.58M vs. $200.04M), but analysts’ consensus rating remains a “Hold” with an average target of $101.41.

Inspire Medical Systems (NYSE:INSP - Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.750-1.250 for the period, compared to the consensus estimate of 1.990. The company issued revenue guidance of $825.0 million-$875.0 million, compared to the consensus revenue estimate of $961.2 million.

Inspire Medical Systems Trading Down 3.4%

NYSE:INSP traded down $1.93 during trading hours on Monday, hitting $54.77. 1,477,111 shares of the stock were exchanged, compared to its average volume of 1,173,139. Inspire Medical Systems has a 52-week low of $48.30 and a 52-week high of $163.35. The firm's fifty day moving average price is $56.73 and its 200 day moving average price is $79.64. The company has a market cap of $1.58 billion, a P/E ratio of 11.00, a P/E/G ratio of 2.92 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The company had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities analysts expect that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on INSP. Zacks Research lowered shares of Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 14th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $56.00 price target on shares of Inspire Medical Systems in a report on Tuesday, April 14th. UBS Group set a $67.00 price target on Inspire Medical Systems in a report on Friday, February 13th. Morgan Stanley set a $60.00 price target on Inspire Medical Systems in a report on Wednesday, February 18th. Finally, Evercore reaffirmed an "outperform" rating on shares of Inspire Medical Systems in a report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inspire Medical Systems has a consensus rating of "Hold" and an average target price of $101.41.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its position in shares of Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after acquiring an additional 205 shares during the last quarter. Daiwa Securities Group Inc. increased its position in shares of Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after acquiring an additional 130 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Inspire Medical Systems by 21,266.7% during the third quarter. Larson Financial Group LLC now owns 641 shares of the company's stock valued at $48,000 after acquiring an additional 638 shares during the last quarter. Quarry LP increased its position in shares of Inspire Medical Systems by 695.1% during the fourth quarter. Quarry LP now owns 644 shares of the company's stock valued at $59,000 after acquiring an additional 563 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in shares of Inspire Medical Systems by 349.7% during the fourth quarter. Parallel Advisors LLC now owns 715 shares of the company's stock valued at $66,000 after acquiring an additional 556 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.